FDA approves hyaluronic acid lip filler Restylane Kysse.
Morgan Petronelli, May 6, 2020
“Restylane Kysse is a new lip filler that offers key attributes both providers and their patients desire in a lip injection – high satisfaction, consistent results and a proven clinical-safety profile,” says Alisa Lask, general manager and vice president of the U.S. Aesthetic Business at Galderma.
Revance to introduce TEOXANE RHA® fillers in the U.S.
Katie Hobbins, Jan 13, 2020
“Revance Therapeutics, a biotechnology company specializing in neuromodulator innovations, recently announced a U.S. distribution agreement with Swiss hyaluronic acid (HA)-based dermal filler manufacturing company, TEOXANE SA.
The partnership gives Revance immediate and exclusive access to the company’s range of Resilient HA (RHA) fillers in the United States, with TEOXANE gaining 2.5 million shares of Revance common stock in return, according to the press release.”
Brotox: the new job security for men?
FOXBusiness, Aug 3, 2019
“Job security is a real concern among aging employees in the workplace but there’s a discreet trend among men who want to stay competitive in today’s tightening job market.
It’s called Brotox. That’s right, botox for men.”
Bellus Medical, the Aesthetics Division of Crown Laboratories, Announces Acquisition of Healeon Medical’s HD PRP System for Aesthetic Marketplace
PRNewswire: DALLAS, May 23, 2019
Bellus Medical is proud to announce the acquisition of Healeon Medical, Inc.’s HD PRP system for the aesthetic marketplace. This specialized system is designed to meet the demands of busy practices seeking higher volume and higher yield Platelet Rich Plasma procedures; with the most efficient and convenient system on the market. As part of their expanding Platelet Rich Plasma portfolio, Bellus Medical will re-brand their suite of offerings as the ProGen PRP™ Advantage and ProGen PRP™ Versa lines; both high-yield systems for use in Platelet Rich Plasma procedures.
New Injectable Neurotoxin Cleared for Spring 2019 Launch
Jeff Frentzen, Feb 1, 2019
The U.S. aesthetic neurotoxin marketplace is set to expand somewhat dramatically in 2019. On February 1, 2019, Evolus, Inc. (Irvine, Calif.), announced the FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), its injectable neurotoxin for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity in adults.
Evolus Receives FDA Approval for Jeuveau™ prabotulinumtoxinA-xvfs for Injection
Evolus, Feb 1, 2019
NEWPORT BEACH, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) — Evolus, Inc. (NASDAQ: EOLS) today announced that the U.S. Food and Drug Administration (“FDA”) has approved its lead product, Jeuveau™, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.
Prollenium US Announces the Release of Revanesse Versa + With Lidocaine
RALEIGH, N.C., Dec. 17, 2018 /PRNewswire/ — Prollenium® US is proud to announce the immediate availability of Revanesse® Versa +™. Revanesse® Versa +™ has been developed due to high levels of provider and patient interest in a dermal filler with all the benefits of Revanesse® Versa™ plus the addition of Lidocaine.
Galderma Launches Restylane® Silk – First and Only FDA Approved Filler Indicated for Lip Enhancement and Treatment of Perioral Lines
Galderma, Jan 29, 2015
FORT WORTH, Texas, Jan. 29, 2015 /PRNewswire/ — Galderma, a global healthcare company focused on skin health, today announced the launch of Restylane® Silk, the first and only dermal filler approved by the U.S. Food and Drug Administration (FDA) for lip enhancement and the treatment of wrinkles and lines around the mouth in people over the age of 21. Restylane® Silk is a smooth gel designed to restore natural youthful definition and symmetry to the lip and mouth area.